亚洲日本一区二区三区在线播放-国产一区二区色淫影院-久久综合久久88-亚洲国产人成自久久国产-久久国产高清一区二区三区-自拍偷拍亚洲综合视频-精品久久久av免费观看

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

国产偷窥熟女精品视频大全 | 波多野结衣高清无碼中文字幕 | 欧洲精欧洲精品高清一区 | 天堂tv亚洲tv日本tv不卡 | 国内精品久久久久影院老司 | 日本三级带日本三级带黄国产 | 在线精品自偷自拍无码 | 精品久久久久久久久久中文字幕 | 欧美人与性囗牲恔配 | 狠狠综合久久综合88亚洲 | 国精品午夜福利视频不卡麻豆 | 亚洲 校园 欧美 国产 另类 | 最近中文字幕mv免费视频 | 91精品国产无码高清 | 国产麻豆精品精东影业AV网站 | 国产美女一区二区 | 欧美三級片黃色三級片黃色 | 婷婷五月天激情综合影院 | 欧美综合中文字幕久久99 | 男人裸身露j不挡的图片 | 四虎影视一区二区精品 | 亚洲一级毛片无码专区 | 免费又黄又裸乳的gif动态图 | 在电影院嗯啊挺进去了啊视频 | 国产无套内射又大又猛又粗又爽 | 亚洲色欲色欲WWW成人网麻豆 | 狠狠色综合久久久久尤物 | 国产又黄又大又粗的视频 | 高清无码视频在线观看 | 牛牛影视午夜免费福利 | 国产真实老熟女无套内射 | 青青草97国产精品免费观看 | 直接看的av网址免费的 | 麻豆一区产品精品蜜桃的广告语 | 亚洲精品乱码久久久久66国产成 | 亚洲女精品一区二区三区 | 欧美性猛交XXXX乱大交3 | 国产成人午夜极速观看 | 人人揉人人捏人人爽五月天 | 欧美精品精品一区在线发布 | 久久久无码精品国产H动漫 亚洲AV无码一区二区三区在线高 |